EA038984B1 - Расщепляемые конъюгаты полимера и лекарственного средства - Google Patents

Расщепляемые конъюгаты полимера и лекарственного средства Download PDF

Info

Publication number
EA038984B1
EA038984B1 EA201990142A EA201990142A EA038984B1 EA 038984 B1 EA038984 B1 EA 038984B1 EA 201990142 A EA201990142 A EA 201990142A EA 201990142 A EA201990142 A EA 201990142A EA 038984 B1 EA038984 B1 EA 038984B1
Authority
EA
Eurasian Patent Office
Prior art keywords
formula
polymer
group
drug conjugate
natural number
Prior art date
Application number
EA201990142A
Other languages
English (en)
Russian (ru)
Other versions
EA201990142A1 (ru
Inventor
Рана Саньял
Амитав Саньял
Мехмет Арслан
Бурджу Сумер Болу
Озгул Гок
Мерве Караджывы
Садик Кага
Original Assignee
Рс Арастирма Эгитим Данисманлик Иладж Санайи Тиджарет Аноним Сиркети
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Рс Арастирма Эгитим Данисманлик Иладж Санайи Тиджарет Аноним Сиркети filed Critical Рс Арастирма Эгитим Данисманлик Иладж Санайи Тиджарет Аноним Сиркети
Publication of EA201990142A1 publication Critical patent/EA201990142A1/ru
Publication of EA038984B1 publication Critical patent/EA038984B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F220/00—Copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and only one being terminated by only one carboxyl radical or a salt, anhydride ester, amide, imide or nitrile thereof
    • C08F220/02—Monocarboxylic acids having less than ten carbon atoms; Derivatives thereof
    • C08F220/10—Esters
    • C08F220/26—Esters containing oxygen in addition to the carboxy oxygen
    • C08F220/28—Esters containing oxygen in addition to the carboxy oxygen containing no aromatic rings in the alcohol moiety
    • C08F220/285—Esters containing oxygen in addition to the carboxy oxygen containing no aromatic rings in the alcohol moiety and containing a polyether chain in the alcohol moiety
    • C08F220/286—Esters containing oxygen in addition to the carboxy oxygen containing no aromatic rings in the alcohol moiety and containing a polyether chain in the alcohol moiety and containing polyethylene oxide in the alcohol moiety, e.g. methoxy polyethylene glycol (meth)acrylate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A61K31/09—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon having two or more such linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F220/00—Copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and only one being terminated by only one carboxyl radical or a salt, anhydride ester, amide, imide or nitrile thereof
    • C08F220/02—Monocarboxylic acids having less than ten carbon atoms; Derivatives thereof
    • C08F220/52—Amides or imides
    • C08F220/54—Amides, e.g. N,N-dimethylacrylamide or N-isopropylacrylamide
    • C08F220/60—Amides, e.g. N,N-dimethylacrylamide or N-isopropylacrylamide containing nitrogen in addition to the carbonamido nitrogen
    • C08F220/603—Amides, e.g. N,N-dimethylacrylamide or N-isopropylacrylamide containing nitrogen in addition to the carbonamido nitrogen and containing oxygen in addition to the carbonamido oxygen and nitrogen
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F222/00—Copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a carboxyl radical and containing at least one other carboxyl radical in the molecule; Salts, anhydrides, esters, amides, imides, or nitriles thereof
    • C08F222/10—Esters
    • C08F222/1006—Esters of polyhydric alcohols or polyhydric phenols
    • C08F222/106—Esters of polycondensation macromers
    • C08F222/1063—Esters of polycondensation macromers of alcohol terminated polyethers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Polymers & Plastics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Macromonomer-Based Addition Polymer (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
EA201990142A 2016-06-30 2017-06-15 Расщепляемые конъюгаты полимера и лекарственного средства EA038984B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB1611405.0A GB2551979A (en) 2016-06-30 2016-06-30 Cleavable polymer drug conjugates
PCT/IB2017/053567 WO2018002761A1 (en) 2016-06-30 2017-06-15 Cleavable polymer drug conjugates

Publications (2)

Publication Number Publication Date
EA201990142A1 EA201990142A1 (ru) 2019-06-28
EA038984B1 true EA038984B1 (ru) 2021-11-18

Family

ID=56891421

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201990142A EA038984B1 (ru) 2016-06-30 2017-06-15 Расщепляемые конъюгаты полимера и лекарственного средства

Country Status (19)

Country Link
US (1) US20190321479A1 (enExample)
EP (2) EP4260874A1 (enExample)
JP (1) JP6937329B2 (enExample)
KR (3) KR20230035709A (enExample)
CN (1) CN109475637A (enExample)
AU (1) AU2017286869B2 (enExample)
CA (1) CA3029318A1 (enExample)
DK (1) DK3478323T3 (enExample)
EA (1) EA038984B1 (enExample)
ES (1) ES2966774T3 (enExample)
FI (1) FI3478323T3 (enExample)
GB (1) GB2551979A (enExample)
HR (1) HRP20231642T1 (enExample)
HU (1) HUE064705T2 (enExample)
IL (3) IL321408A (enExample)
MX (2) MX2019000277A (enExample)
PL (1) PL3478323T3 (enExample)
PT (1) PT3478323T (enExample)
WO (1) WO2018002761A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8765432B2 (en) 2009-12-18 2014-07-01 Oligasis, Llc Targeted drug phosphorylcholine polymer conjugates
GB2556055B (en) 2016-11-16 2022-03-23 Rs Arastirma Egitim Danismanlik Ilac Sanayi Ticaret Ltd Sti Self-assembled diblock copolymers composed of pegmema and drug bearing polymeric segments
US12150996B2 (en) * 2017-11-17 2024-11-26 Centre National De La Recherche Scientifique Polymeric prodrugs and subcutaneous and/or intramuscular administration thereof
CN108752507A (zh) * 2018-05-12 2018-11-06 辽宁大学 一种酶敏感和氧化还原敏感双重响应型共聚物及其制备方法和应用
TR201911542A2 (tr) * 2019-07-30 2021-02-22 Bogazici Ueniversitesi Anti̇kor-poli̇mer konjugatlari
JP2022549680A (ja) * 2019-09-26 2022-11-28 スターファーマ ピーティーワイ エルティーディー 治療用デンドリマー
CN112608364B (zh) * 2020-12-09 2023-08-29 四川瀛瑞医药科技有限公司 一种果胶-阿霉素轭合物及其中间体的制备方法
CN115010913B (zh) * 2022-06-17 2023-05-26 广东工业大学 一种pH/还原双重响应聚合物胶束及其制备方法与应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007028347A2 (en) * 2005-09-05 2007-03-15 Zentiva, A.S. Method for the preparation of polymeric conjugates of doxorubicin with ph- controlled release of the drug
WO2010091650A1 (en) * 2009-02-13 2010-08-19 Zentiva, K.S. Polymeric conjugates of paclitaxel and docetaxel with ph-controlled releasing of the cancerostatic agent

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19636889A1 (de) 1996-09-11 1998-03-12 Felix Dr Kratz Antineoplastisch wirkende Transferrin- und Albuminkonjugate zytostatischer Verbindungen aus der Gruppe der Anthrazykline, Alkylantien, Antimetabolite und Cisplatin-Analoga und diese enthaltende Arzneimittel
ATE317703T1 (de) 1997-06-12 2006-03-15 Innovata Plc Polymer-wirkstoff-konjugate zur behandlung von krebs
CN1308347C (zh) 1999-04-28 2007-04-04 德克萨斯大学董事会 用于通过选择性抑制vegf来治疗癌症的组合物和方法
US20030215395A1 (en) 2002-05-14 2003-11-20 Lei Yu Controllably degradable polymeric biomolecule or drug carrier and method of synthesizing said carrier
US8017141B2 (en) * 2006-12-15 2011-09-13 Advanced Cardiovascular Systems, Inc. Coatings of acrylamide-based copolymers
AU2009302387B2 (en) * 2008-10-07 2014-12-04 Rexahn Pharmaceuticals, Inc HPMA - docetaxel or gemcitabine conjugates and uses therefore
BR112012008772A2 (pt) * 2009-10-13 2017-06-20 Rexahn Pharmaceuticals Inc sistemas poliméricos para a liberação de agentes anti-câncer
WO2012014003A1 (en) * 2010-07-28 2012-02-02 Corning Incorporated Pre-polymer preparations for cell culture coatings
WO2014152451A2 (en) * 2013-03-14 2014-09-25 University Of Rochester Compositions and methods for controlled localized delivery of bone forming therapeutic agents
CN105168230B (zh) * 2015-09-02 2019-01-22 上海市普陀区中心医院 一种具有内涵体逃逸功能的肿瘤靶向前药及其纳米制剂和制备方法

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007028347A2 (en) * 2005-09-05 2007-03-15 Zentiva, A.S. Method for the preparation of polymeric conjugates of doxorubicin with ph- controlled release of the drug
WO2010091650A1 (en) * 2009-02-13 2010-08-19 Zentiva, K.S. Polymeric conjugates of paclitaxel and docetaxel with ph-controlled releasing of the cancerostatic agent

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
ANDREA SEEHUBER, DENNIS SCHMIDT, REINER DAHINT: "Poly(acrylic acid)–Poly(ethylene glycol) Layers on Positively Charged Surface Coatings: Molecular Structure, Protein Resistance, and Application to Single Protein Deposition", LANGMUIR, AMERICAN CHEMICAL SOCIETY, vol. 28, no. 23, 12 June 2012 (2012-06-12), pages 8700 - 8710, XP055098947, ISSN: 07437463, DOI: 10.1021/la2050652 *
ANDREAS KRIEG , CHRISTIAN PIETSCH , ANJA BAUMGAERTEL , MARTIN D. HAGER , C. REMZI BECER , ULRICH S. SCHUBERT: "Dual hydrophilic polymers based on (meth)acrylic acid and poly(ethylene glycol) - synthesis and water uptake behavior", POLYMER CHEMISTRY, vol. 1, 8 September 2010 (2010-09-08), pages 1669 - 1676, XP002774790, DOI: 10.1039/c0py00156b *
KOPECEK, J. KOPECKOVA, P. MINKO, T. LU, Z.-R.: "HPMA copolymer-anticancer drug conjugates: design, activity, and mechanism of action", EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, ELSEVIER SCIENCE PUBLISHERS B.V., AMSTERDAM., NL, vol. 50, no. 1, 3 July 2000 (2000-07-03), NL , pages 61 - 81, XP004257180, ISSN: 0939-6411, DOI: 10.1016/S0939-6411(00)00075-8 *
KUSCH P. ET AL.: "Characterization of copolymers of methacrylic acid with poly(ethylene glycol) methyl ether methacrylate macromonomers by analytical pyrolysis-gas chromatography/mass spectrometry (Py-GC/MS)", JOURNAL OF ANALYTICAL AND APPLIED PYROLYSIS, vol. 113, 10 March 2015 (2015-03-10), pages 412 - 418, XP002774788, DOI: 10.1016/j.jaap.2015.03.003 *
SCHMOLKE H.: "Poly(acrylic acid)-graft-poly(ethylene glycol) preparation and adsorption on polyelectrolyte multilayers (PEMs) for custom-made antiadhesive surfaces", PHYSICA STATUS SOLIDI A, vol. 208, no. 6, 11 May 2011 (2011-05-11), pages 1290 - 1300, XP002774789, DOI: 10.1002/pssa.201100002 *

Also Published As

Publication number Publication date
DK3478323T3 (da) 2024-01-02
PT3478323T (pt) 2024-01-02
AU2017286869A1 (en) 2019-02-07
EP3478323A1 (en) 2019-05-08
IL263965B2 (en) 2023-10-01
KR20190022718A (ko) 2019-03-06
GB2551979A (en) 2018-01-10
IL302564A (en) 2023-07-01
IL302564B2 (en) 2025-11-01
CA3029318A1 (en) 2018-01-04
IL263965B1 (en) 2023-06-01
HRP20231642T1 (hr) 2024-03-15
EP3478323B1 (en) 2023-09-27
KR20230035709A (ko) 2023-03-14
GB201611405D0 (en) 2016-08-17
MX2019000277A (es) 2019-05-27
IL263965A (en) 2019-01-31
JP2019527209A (ja) 2019-09-26
WO2018002761A1 (en) 2018-01-04
CN109475637A (zh) 2019-03-15
BR112019000029A2 (pt) 2019-04-24
FI3478323T3 (fi) 2023-12-20
PL3478323T3 (pl) 2024-03-04
ES2966774T3 (es) 2024-04-24
EA201990142A1 (ru) 2019-06-28
AU2017286869B2 (en) 2022-05-05
KR102539137B1 (ko) 2023-06-01
MX2024000877A (es) 2024-02-09
IL321408A (en) 2025-08-01
US20190321479A1 (en) 2019-10-24
KR20250084234A (ko) 2025-06-10
EP4260874A1 (en) 2023-10-18
HUE064705T2 (hu) 2024-04-28
AU2017286869A8 (en) 2019-02-14
IL302564B1 (en) 2025-07-01
JP6937329B2 (ja) 2021-09-22

Similar Documents

Publication Publication Date Title
AU2017286869B2 (en) Cleavable polymer drug conjugates
JP7467548B2 (ja) Ｐｅｇｍｅｍａ及び薬物担持ポリマーセグメントから構成される自己集合化ジブロックコポリマー
BR122024016269A2 (pt) Conjugado polímero-fármaco, métodos para preparar o mesmo, composição farmacêutica que compreende o dito conjugado, bem como uso do mesmo para tratamento e/ou profilaxia de câncer
BR112019000029B1 (pt) Conjugado polímero-fármaco, métodos para preparar o mesmo, composição farmacêutica que compreende o dito conjugado, bem como o uso do mesmo para o tratamento e/ou a profilaxia de câncer
EA044119B1 (ru) Претерпевшие самосборку диблок-сополимеры, состоящие из pegmema и несущих лекарственное средство полимерных сегментов